<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Xencor</title>
	<atom:link href="http://www.xencor.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xencor.com</link>
	<description>Proteins By Design</description>
	<lastBuildDate>Sat, 12 May 2012 00:38:42 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.5</generator>
		<item>
		<title>09.24.12 &#8211; 09.26.12</title>
		<link>http://www.xencor.com/2012/05/09-24-2012-09-26-2012/</link>
		<comments>http://www.xencor.com/2012/05/09-24-2012-09-26-2012/#comments</comments>
		<pubDate>Sat, 12 May 2012 00:35:24 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1924</guid>
		<description><![CDATA[SMi&#8217;s Biosimilars and Biobetters (David E. Szymkowski, Ph.D., presenting; London, UK)]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/05/09-24-2012-09-26-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration</title>
		<link>http://www.xencor.com/2012/04/xencor-receives-milestone-payment-from-csl-limited-under-antibody-optimization-collaboration/</link>
		<comments>http://www.xencor.com/2012/04/xencor-receives-milestone-payment-from-csl-limited-under-antibody-optimization-collaboration/#comments</comments>
		<pubDate>Thu, 19 Apr 2012 17:18:35 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PRESS RELEASES]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1917</guid>
		<description><![CDATA[SEVENTH ANTIBODY DEVELOPED WITH XENCOR&#8217;S XmAb TECHNOLOGY MOVES INTO HUMAN TRIALS MONROVIA, Calif., April 19, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under an antibody optimization collaboration agreement with CSL Limited. The payment was &#8230; <a href="http://www.xencor.com/2012/04/xencor-receives-milestone-payment-from-csl-limited-under-antibody-optimization-collaboration/">&#8230;</a>]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/04/xencor-receives-milestone-payment-from-csl-limited-under-antibody-optimization-collaboration/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>05.20.12 &#8211; 05.23.12</title>
		<link>http://www.xencor.com/2012/04/05-20-12-05-23-12/</link>
		<comments>http://www.xencor.com/2012/04/05-20-12-05-23-12/#comments</comments>
		<pubDate>Mon, 09 Apr 2012 22:53:08 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1912</guid>
		<description><![CDATA[4th DIA China Annual Meeting (Bassil Dahiyat, Ph.D., Speaker; Shanghai, China)]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/04/05-20-12-05-23-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement</title>
		<link>http://www.xencor.com/2012/04/1903/</link>
		<comments>http://www.xencor.com/2012/04/1903/#comments</comments>
		<pubDate>Wed, 04 Apr 2012 15:27:49 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PRESS RELEASES]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1903</guid>
		<description><![CDATA[MONROVIA, Calif., April 4, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.  The payment was triggered by a regulatory submission to begin Phase 1 clinical trials of &#8230; <a href="http://www.xencor.com/2012/04/1903/">&#8230;</a>]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/04/1903/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>03.26.12 – 03.28.12</title>
		<link>http://www.xencor.com/2012/03/03-26-12-%e2%80%93-03-28-12/</link>
		<comments>http://www.xencor.com/2012/03/03-26-12-%e2%80%93-03-28-12/#comments</comments>
		<pubDate>Tue, 13 Mar 2012 23:33:57 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1667</guid>
		<description><![CDATA[24th Annual EuroMeeting, Drug Information Association (David Szymkowski, Ph.D., presenting; Copenhagen, Denmark)]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/03/03-26-12-%e2%80%93-03-28-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>03.25.12 &#8211; 03.30.12</title>
		<link>http://www.xencor.com/2012/03/03-25-12-03-30-12/</link>
		<comments>http://www.xencor.com/2012/03/03-25-12-03-30-12/#comments</comments>
		<pubDate>Mon, 12 Mar 2012 23:07:36 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1778</guid>
		<description><![CDATA[Gordon Research Conference &#8211; Antibody Biology &#038; Engineering (John Desjarlais, Ph.D., presenting; Galveston, TX)]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/03/03-25-12-03-30-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>03.19.12 – 03.22.12</title>
		<link>http://www.xencor.com/2012/03/03-19-12-%e2%80%93-03-22-12/</link>
		<comments>http://www.xencor.com/2012/03/03-19-12-%e2%80%93-03-22-12/#comments</comments>
		<pubDate>Sun, 11 Mar 2012 20:38:04 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1818</guid>
		<description><![CDATA[IBC’s 3rd Biotherapeutics Analytical Summit (David Szymkowski, Ph.D., presenting; Baltimore, MD)]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/03/03-19-12-%e2%80%93-03-22-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>02.29.12 – 03.02.12</title>
		<link>http://www.xencor.com/2012/02/02-29-12-%e2%80%93-03-02-12/</link>
		<comments>http://www.xencor.com/2012/02/02-29-12-%e2%80%93-03-02-12/#comments</comments>
		<pubDate>Thu, 01 Mar 2012 00:31:11 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1663</guid>
		<description><![CDATA[IBC’s 28th International Antibody Development &#38; Production (David Szymkowski, Ph.D., presenting; San Diego, CA)]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/02/02-29-12-%e2%80%93-03-02-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>02.29.12 &#8211; 03.02.12</title>
		<link>http://www.xencor.com/2012/02/02-29-12-03-02-12/</link>
		<comments>http://www.xencor.com/2012/02/02-29-12-03-02-12/#comments</comments>
		<pubDate>Wed, 29 Feb 2012 18:36:43 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1751</guid>
		<description><![CDATA[Biobetters &#38; Biosimilars – Technologies &#38; Development Strategies (Bassil Dahiyat, Ph.D., presenting; San Diego, CA)]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/02/02-29-12-03-02-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies</title>
		<link>http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/</link>
		<comments>http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/#comments</comments>
		<pubDate>Tue, 21 Feb 2012 16:54:01 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PRESS RELEASES]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1852</guid>
		<description><![CDATA[Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life MONROVIA, Calif., USA and INGELHEIM, Germany – February 21, 2012 – Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and &#8230; <a href="http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/">&#8230;</a>]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

